Johann Jakob Wendler1, Jens Ricke2, Maciej Pech3, Frank Fischbach4, Julian Jürgens5, Sandra Siedentopf6, Albert Roessner7, Markus Porsch8, Daniel Baumunk9, Martin Schostak10, Jens Köllermann11, Uwe-Bernd Liehr12. 1. Department of Urology, University Hospital, Otto von Guericke University of Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. johann.wendler@med.ovgu.de. 2. Department of Radiology, University of Magdeburg, Magdeburg, Germany. jens.Ricke@med.ovgu.de. 3. Department of Radiology, University of Magdeburg, Magdeburg, Germany. macej.pech@med.ovgu.de. 4. Department of Radiology, University of Magdeburg, Magdeburg, Germany. frank.fischbach@med.ovgu.de. 5. Department of Radiology, University of Magdeburg, Magdeburg, Germany. julian.juergens@med.ovgu.de. 6. Institute of Pathology, University of Magdeburg, Magdeburg, Germany. sandra.siedentopf@med.ovgu.de. 7. Institute of Pathology, University of Magdeburg, Magdeburg, Germany. albert.roessner@med.ovgu.de. 8. Department of Urology, University Hospital, Otto von Guericke University of Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. markus.porsch@med.ovgu.de. 9. Department of Urology, University Hospital, Otto von Guericke University of Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. daniel.baumunk@med.ovgu.de. 10. Department of Urology, University Hospital, Otto von Guericke University of Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. martin.schostak@med.ovgu.de. 11. Institute of Pathology, Sana Klinikum Offenbach Am Main, Offenbach Am Main, Germany. jens.koellermann@sana.de. 12. Department of Urology, University Hospital, Otto von Guericke University of Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. uwe-bernd.liehr@med.ovgu.de.
Abstract
INTRODUCTION: It is postulated that focal IRE affords complete ablation of soft-tissue tumours while protecting the healthy peritumoral tissue. Therefore, IRE may be an interesting option for minimally invasive, kidney-tissue-sparing, non-thermal ablation of renal tumours. AIM: With this current pilot study ("IRENE trial"), we present the first detailed histopathological data of IRE of human RCC followed by delayed tumour resection. The aim of this interim analysis of the first three patients was to investigate the ablation efficiency of percutaneous image-guided focal IRE in RCC, to assess whether a complete ablation of T1a RCC and tissue preservation with the NanoKnife system is possible and to decide whether the ablation parameters need to be altered. METHODS: Following resection 4 weeks after percutaneous IRE, the success of ablation and detailed histopathological description were used to check the ablation parameters. RESULTS: The IRE led to a high degree of damage to the renal tumours (1 central, 2 peripheral; size range 15-17 mm). The postulated homogeneous, isomorphic damage was only partly confirmed. We found a zonal structuring of the ablation zone, negative margins and, enclosed within the ablation zone, very small tumour residues of unclear malignancy. CONCLUSION: According to these initial, preliminary study results of the first three renal cases, a new zonal distribution of IRE damage was described and the curative intended, renal saving focal ablation of localised RCC below <3 cm by percutaneous IRE by the NanoKnife system appears to be possible, but needs further, systematic evaluation for this treatment method and treatment protocol.
INTRODUCTION: It is postulated that focal IRE affords complete ablation of soft-tissue tumours while protecting the healthy peritumoral tissue. Therefore, IRE may be an interesting option for minimally invasive, kidney-tissue-sparing, non-thermal ablation of renal tumours. AIM: With this current pilot study ("IRENE trial"), we present the first detailed histopathological data of IRE of humanRCC followed by delayed tumour resection. The aim of this interim analysis of the first three patients was to investigate the ablation efficiency of percutaneous image-guided focal IRE in RCC, to assess whether a complete ablation of T1a RCC and tissue preservation with the NanoKnife system is possible and to decide whether the ablation parameters need to be altered. METHODS: Following resection 4 weeks after percutaneous IRE, the success of ablation and detailed histopathological description were used to check the ablation parameters. RESULTS: The IRE led to a high degree of damage to the renal tumours (1 central, 2 peripheral; size range 15-17 mm). The postulated homogeneous, isomorphic damage was only partly confirmed. We found a zonal structuring of the ablation zone, negative margins and, enclosed within the ablation zone, very small tumour residues of unclear malignancy. CONCLUSION: According to these initial, preliminary study results of the first three renal cases, a new zonal distribution of IRE damage was described and the curative intended, renal saving focal ablation of localised RCC below <3 cm by percutaneous IRE by the NanoKnife system appears to be possible, but needs further, systematic evaluation for this treatment method and treatment protocol.
Entities:
Keywords:
Ablation; Focal therapy (FT); Irreversible electroporation (IRE); Kidney; Renal cell carcinoma (RCC); Small renal mass (SRM)
Authors: Erik Velez; S Nahum Goldberg; Gaurav Kumar; Yuanguo Wang; Svetlana Gourevitch; Jacob Sosna; Tyler Moon; Christopher L Brace; Muneeb Ahmed Journal: Radiology Date: 2016-07-13 Impact factor: 11.105
Authors: Noah E Canvasser; Igor Sorokin; Aaron H Lay; Monica S C Morgan; Asim Ozayar; Clayton Trimmer; Jeffrey A Cadeddu Journal: World J Urol Date: 2017-03-02 Impact factor: 4.226
Authors: J J Wendler; B Friebe; D Baumunk; A Blana; T Franiel; R Ganzer; B Hadaschik; T Henkel; K U Köhrmann; J Köllermann; T Kuru; S Machtens; A Roosen; G Salomon; H P Schlemmer; L Sentker; U Witzsch; U B Liehr; J Ricke; M Schostak Journal: Urologe A Date: 2016-05 Impact factor: 0.639
Authors: Mara Buijs; Krijn P van Lienden; Peter Gk Wagstaff; Matthijs Jv Scheltema; Daniel M de Bruin; Patricia J Zondervan; Otto M van Delden; Ton G van Leeuwen; Jean Jmch de la Rosette; M Pilar Laguna Journal: JMIR Res Protoc Date: 2017-02-16
Authors: Peter Gk Wagstaff; Mara Buijs; Willemien van den Bos; Daniel M de Bruin; Patricia J Zondervan; Jean Jmch de la Rosette; M Pilar Laguna Pes Journal: Onco Targets Ther Date: 2016-04-22 Impact factor: 4.147